carfilzomib or bortezomib in relapsed or refractory
Efficacy and safety of carfilzomib-based regimens in frail
Nov 09 2020 · This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib 27 mg/m 2 -lenalidomide-dexamethasone KRd27 vs lenalidomide-dexamethasone Rd ) ENDEAVOR (carfilzomib 56 mg/m 2 -dexamethasone Kd56 vs bortezomib-dexamethasone Vd
Get PriceCarfilzomib versus bortezomib no longer an ENDEAVORThe
Aug 23 2017 · Carfilzomib is an irreversible epoxyketone proteasome inhibitor whereas bortezomib is a reversible boronic acid-based proteasome inhibitor.
Get PriceCarfilzomib or bortezomib in relapsed or refractory
Background The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma.Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis.
Get PriceREFERENCESUpToDate
Jagannath S Richardson PG Barlogie B et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006 91 929.
Get PriceCarfilzomib and dexamethasone versus bortezomib and
BACKGROUND Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients
Get PriceOnce-weekly vs. twice-weekly carfilzomib dosing in a
Oct 10 2020 · Carfilzomib is indicated for the treatment of relapsed and refractory multiple myeloma (RRMM) in combination with dexamethasone (once-weekly carfilzomib 20/70 mg/m 2 or twice-weekly 20/56 mg/m 2 administered as a 30-min infusion) or lenalidomide (Revlimid® Celgene Corp. Summit NJ US) plus dexamethasone (KRd) (carfilzomib 20 mg/m 2
Get PriceCarfilzomib Tops Bortezomib in Relapsed Myeloma
Jun 03 2015 · Carfilzomib has approval in the United States and elsewhere as single-agent therapy in relapsed and refractory myeloma. The approved dosage for carfilzomib is 20 mg/m2 on days 1
Get PriceCarfilzomib or bortezomib in relapsed or refractory
The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis.
Get PriceENDEAVOR Carfilzomib Increases Overall Survival Over
Oct 01 2017 · Previous results from the phase III ENDEAVOR study showed that treatment with the proteasome inhibitor carfilzomib plus dexamethasone extended progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM) compared with bortezomib plus dexamethasone (18.7 months vs. 9.4 months hazard ratio HR = 0.53 95 CI 0.44-0.65 p<0.0001).
Get PriceHealth-related quality of life in the ENDEAVOR study
Carfilzomib is an epoxyketone proteasome inhibitor that binds selectively and irreversibly to the proteasome. The combination of carfilzomib with dexamethasone (twice-weekly carfilzomib dose of
Get PriceCarfilzomib in relapsed or refractory multiple myeloma
In conclusion patients with relapsed or refractory multiple myeloma who received carfilzomib-containing regimens had improved PFS and ORR compared with control groups regardless of whether they had an early or late relapse following the most recent prior therapy.
Get PriceTreating Relapsed and/or Refractory Multiple Myeloma in
Oct 09 2020 · Because of the absolute magnitude of benefits daratumumab followed by carfilzomib-based combinations emerge as the most efficacious regimens and preferred initial options in patients with early relapse. The choice of treatment however is individualized.
Get PriceA Phase 2 Study of Bortezomib in Relapsed Refractory
In this phase 2 trial we evaluated the efficacy of bortezomib in patients with relapsed refractory myeloma. The overall response rate including complete responses was 35 percent.
Get PriceA real‐world efficacy and safety analysis of combined
Oct 21 2020 · Carfilzomib–lenalidomide–dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian hematologic centers with the aim to evaluate efficacy and safety of KRd in real‐life.
Get PriceCarfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone
The phase III RandomizEd OpeN Label Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m 2) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or
Get PriceTreatment of relapsed/refractory multiple myeloma in the
Jan 11 2021 · Dimopoulos M Quach H Mateos MV Landgren O Leleu X Siegel D Weisel K Yang H Klippel Z Zahlten-Kumeli A Usmani SZ (2020) Carfilzomib dexamethasone and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) results from a randomised multicentre open-label phase 3 study.
Get PriceRenal response in real-world carfilzomib- vs bortezomib
Jan 19 2021 · In the phase 3 ENDEAVOR study carfilzomib-dexamethasone (Kd) improved survival over bortezomib-dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM) regardless of baseline renal function.
Get PriceCarfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone
Aug 01 2019 · The phase III RandomizEd OpeN Label Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m 2) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma
Get PriceOpen Access Full Text Article Carfilzomib a novel
Abstract Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has signifi-cant efficacy in bortezomib
Get PriceCarfilzomib or bortezomib in relapsed or refractory
ENDEAVOR compared carfilzomib administered at 56 mg/m 2 over a 30-min infusion twice per week with dexamethasone against bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who had received between one and three previous treatments.
Get PriceREFERENCESUpToDate
Jagannath S Richardson PG Barlogie B et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006 91 929.
Get PriceEfficacy and safety of carfilzomib-based regimens in frail
Nov 09 2020 · This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib 27 mg/m 2 -lenalidomide-dexamethasone KRd27 vs lenalidomide-dexamethasone Rd ) ENDEAVOR (carfilzomib 56 mg/m 2 -dexamethasone Kd56 vs bortezomib-dexamethasone Vd
Get PriceCarfilzomib or bortezomib in relapsed or refractory
The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis.
Get PriceA phase I study of carfilzomib in combination with
The primary objective of this phase I study was to determine the safety profile of the combination of carfilzomib and ibrutinib in patients with relapsed or refractory MCL. A 3 3 study design was planned to examine five primary dose levels (Table 1 ).
Get PriceCarfilzomib in relapsed or refractory multiple myeloma
In conclusion patients with relapsed or refractory multiple myeloma who received carfilzomib-containing regimens had improved PFS and ORR compared with control groups regardless of whether they had an early or late relapse following the most recent prior therapy.
Get PriceCarfilzomib versus bortezomib no longer an ENDEAVORThe
Aug 23 2017 · Carfilzomib is an irreversible epoxyketone proteasome inhibitor whereas bortezomib is a reversible boronic acid-based proteasome inhibitor.
Get PricePhase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib
The study met the key secondary endpoint of OS demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS ® (carfilzomib) and dexamethasone (Kd) lived 7.6 months longer than those treated with Velcade ® (bortezomib) and dexamethasone (Vd) (median OS 47.6 months for Kd versus 40.0 for Vd HR = 0.79 95
Get PriceNavigating the Increasing Complexity of Therapeutic
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) a randomised phase 3 open-label multicentre study.
Get PriceA phase I study of carfilzomib in combination with
The primary objective of this phase I study was to determine the safety profile of the combination of carfilzomib and ibrutinib in patients with relapsed or refractory MCL. A 3 3 study design was planned to examine five primary dose levels (Table 1 ).
Get PriceCarfilzomib or bortezomib in relapsed or refractory
The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis.
Get PriceCarfilzomib for Relapsed and Refractory Multiple Myeloma
May 31 2019 · Proteasome inhibition is a highly effective treatment for MM. Almost 15 years ago the US Food and Drug Administration (FDA) approved the first PI bortezomib for the treatment of relapsed
Get Price
